MPLT

MapLight Therapeutics, Inc. Common Stock

Nasdaq · usd

$7.84-0.14 (-1.69%)

As of 2:23:54 PM EDT on Oct 26, 2026 · 15-minute delayed

MapLight Therapeutics, Inc. Common Stock (MPLT) trades at $7.84 (-1.69%) as of 2:23:54 PM EDT on Oct 26, 2026, -25.72% over the past month. Market cap is $442.94M, with 5.8 days to cover in short interest.

Stock performance

How MapLight Therapeutics, Inc. Common Stock (MPLT) stock has performed from one day to one year, with its 52-week range.

-2.39%

-$0.19 over 1D

1D: -2.51%
1W: -2.88%
1M: -25.72%
YTD: -55.76%
1Y: -57.63%
52-wk range: $7.46 – $40.43

Key statistics

Today's trading snapshot for MPLT: day range, open, previous close, volume and market cap.

Day range: $7.70 – $8.34
Open: $7.98
Prev close: $7.97
Volume: 131.29K
Market cap: $442.94M
Shares out: 55.58M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for MapLight Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E: —
P/S: —
P/B: 1.27
P/FCF: —
ROE: -66.0%
ROA: -62.4%
Debt/Equity: 0.00
Div yield: 0.00%

As of Oct 23, 2026

Insider buying and selling

In the 12 months to Oct 26, 2026, 8 MPLT insiders reported open-market sales of $18.5M across 25 filings; 5 insiders bought $174.9M.

Who traded MPLT, and when

Purchase
Sale
Sale, pre-arranged (10b5-1)

MPLT daily closelast $7.77

Catalyst4, Inc. · 10% owner

$157.9M bought

Novo Holdings A/S · 10% owner

$16.2M bought

Christopher A. Kroeger · Chief Executive Officer

$7.1M sold

Jonathan Gillis · CAAO and PAO → CAO and Interim CFO

$2.9M sold

George Pavlov · Director

$441.2K bought

Timothy John Garnett · Director

$252.7K bought

Troy Cox · Director

$148.7K bought

6 others

$8.5M sold

One row per insider, smaller filers combined; marks sit at the SEC filing date, sized by dollar value.

See who traded and when →

8-K filings

Material corporate events MapLight Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

Underwriting agreementAug 13, 2026
The Company has engaged Morgan Stanley & Co. LLC, Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated as placement agents for the Private Placement. The Company has agreed to pay customary placement fees and reimburse certain expenses of the placement agents.
Investor presentationJul 27, 2026
A copy of the presentation that will accompany the conference call is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
Investor presentationJun 22, 2026
A copy of the presentation that will accompany the conference call is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
Cfo departureJun 18, 2026
On June 18, 2026, Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the "Company"), effective immediately, following a review of a human resources violation.
Investor presentationMay 14, 2026
On May 14, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available on the Company's website and a copy is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

MPLT short interest

How heavily MPLT is shorted: shares short, days to cover and average daily volume.

Days to cover: 5.8
Short interest: 3.15M
Avg volume: 542.98K

As of Sep 30, 2026 · reported to FINRA twice monthly.

MPLT news

The latest news and headlines about MapLight Therapeutics, Inc. Common Stock (MPLT).

MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
neutralThe Motley Fool· May 15, 2026
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
positiveGlobeNewswire Inc.· Jan 9, 2026
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
positiveBenzinga· Oct 29, 2025

About MapLight Therapeutics, Inc. Common Stock

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

ExchangeNasdaq

Marketstocks

TypeCS

CurrencyUSD

IndustryPHARMACEUTICAL PREPARATIONS

Employees133

ListedOct 27, 2025

Company website

Frequently asked questions

What is the MapLight Therapeutics, Inc. Common Stock (MPLT) stock price today?

MapLight Therapeutics, Inc. Common Stock (MPLT) is trading at $7.84 (-1.69% on the day) as of 2:23:54 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is MapLight Therapeutics, Inc. Common Stock?

What is the short interest in MPLT?

As of Sep 30, 2026, MPLT has 3.15M shares short and 5.8 days to cover.

What exchange is MPLT listed on?

MapLight Therapeutics, Inc. Common Stock (MPLT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of MPLT with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Claude ChatGPT

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a MPLT analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.